CLOs on the Move

Bayer Healthcare

www.bayerhealthcare.com

 
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion

Executives

Name Title Contact Details

Similar Companies

Tavotek Biotherapeutics

Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need.

Focus Express Mail Pharmacy Inc

Focus Express Mail Pharmacy Inc is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Azopharma Contract Pharmaceutical Services

Azopharma Contract Pharmaceutical Services is a Miramar, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

JOINN Biologics

JOINN Biologics is a Bay Area, California-based CMO company that is committed to the advancement of biopharmaceutics through its premier contract development and manufacturing services for biologics and advanced therapies. JOINN Biologics aims to provide a complete range of services from early custom development to clinical manufacturing for our global clients. We will work closely with our partners and clients to further accelerate the development of high-quality biologics to meet patient`s needs and deliver long-lasting value to biopharmaceutical industry.

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)